High cardiovascular risk and poor adherence to guidelines in 11 069 patients of middle age and older in primary care centres

European Journal of Preventive Cardiology

Volumn 17, Issue 5, 2010, Pages 593-598

  Missault, Luc ^a   Witters, Nadine ^b   Imschoot, Johan ^b  

^a General Hospital St Jan   (Belgium)

^b Medical Department   (Belgium)

Author keywords

epidemiology; guidelines; prevention; primary care; risk factors; Systematic Coronary Risk Evaluation

Indexed keywords

ARTICLE; BELGIUM; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; HEALTH CARE ACCESS; HYPERCHOLESTEROLEMIA; OBESITY; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK FACTOR; SMOKING; SYSTOLIC BLOOD PRESSURE;

AGED; AMBULATORY CARE; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; BELGIUM; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; DRUG UTILIZATION; FEMALE; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PREVENTIVE HEALTH SERVICES; PRIMARY HEALTH CARE; RISK ASSESSMENT; RISK FACTORS; SMOKING CESSATION;

EID: 77958568026     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/HJR.0b013e328339cc86     Document Type: Article

References (16)

1. Graham I, Atar DE, Borch-Johnsen K, Boysen G, Burelle G, Cifkova R, et al Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical practice (Constituted by representatives of nine societies and by invited experts): European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007; 28: 2375–2414.
2. The SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J 2003; 24: 987–1003.
3. De Backer G, De Bacquer D, Brohet C, De Ceukelier S, Franck A, Krzentowsky G, et al Groupe de Travail Belge de Prévention des Maladies Cardiovasculaires: recommendations relatives a la prévention des maladies cardiovasculaires en pratique clinique. Rev Med Brux 2005; 26: 77–87.
4. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts): European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003; 24: 1601–1610.
5. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U.; On behalf of the EUROASPIRE Study Group. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009; 16: 121–137.
6. EUROASPIRE II Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II. Eur Heart J 2001; 22: 554–572.
7. Malik S, Lopez V, Chen R, Wu W, Wong ND. Undertreatment of cardiovascular risk factors among persons with diabetes in the United States. Diabetes Res Clin Pract 2007; 77: 126–133.
8. Scholte op Reimer W, De Swart E, De Bacquer D, Pyörälä K, Keil U, Heidrich J etal; for the EUROASPIRE investigators. Smoking behaviour in European patients with established coronary heart disease. Eur Heart J 2006; 27: 35–41.
9. Cohen JD. ABCs of secondary prevention of CHD: easier said than done. Lancet 2001; 357: 972–973.
10. De Bacquer D, De Backer G, Cokkinos D, Keil U, Montaye M, Östör E etal; for the EUROASPIRE II Study Group. Overweight and obesity in patients with established coronary heart disease: are we meeting the challenge? Eur Heart J 2004; 25: 121–128.
11. Boersma E, Keil U, De Bacquer D, De Backer G, Pyörälä K, Poldermans D etal; for the EUROASPIRE I and II Study Groups. Blood pressure is insufficiently controlled in European patients with established coronary heart disease. J Hypertens 2003; 21: 1831–1840.
12. Petrella RJ, Merikle E. A retrospective analysis of the prevalence and treatment of hypertension and dyslipidemia in Southwestern Ontario, Canada. Clin Ther 2008; 30: 1145–1154.
13. Mantel-Teeuwisse AK, Verschuren WM, Klungel OH, de Boer A, Kromhout D. Recent trends in (under)treatment of hypercholesterolemia in the Netherlands. Br J Clin Pharmacol 2004; 58: 310–316.
14. Sueta CA, Massing MW, Chowdhury M, Biggs DP, Simpson RJ. Undertreatment of hyperlipidemia in patients with coronary artery disease and heart failure. J Card Fail 2003; 9: 36–41.
15. De Backer G; On behalf of the EUROASPIRE II Study group. Evidence-Evibased goals versus achievement in clinical practice in secondary prevention of coronary heart disease: findings in EUROASPIRE II. Atheroscler Suppl 2002; 2: 13–17.
16. Bittner V. Perspectives on dyslipidemia and coronary heart disease in women: an update. Curr Opin Cardiol 2006; 21: 602–607.